Founded in 2012 by its current CEO and three dermatologists, combining their business and medical backgrounds to address the untapped demand for high quality medical dermatology treatments, Diagnostiskt Centrum Hud (DCH) has established a strong culture focused on clinical excellence and a research-focus covering a broad range of dermatology specialities. DCH is the leading provider in Sweden serving public funded, insurance and private patients.
Bridgepoint Growth has taken a minority stake in the business, providing funding to roll out and acquire new clinics in Sweden and across the Nordic region. The market is underpinned by structural growth drivers, including an ageing population and an increase in the incidence of skin diseases such as skin cancer. DCH focuses on treating melanoma, psoriasis and other severe dermatology conditions.
